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Following primary infection in humans, the human cytomegalovirus (HCMV) persists
in a latent state throughout the host’s lifetime despite a strong and efficient immune
response. If the host experiences some form of immune dysregulation, such as
immunosuppression or immunodeficiency, HCMV reactivates, thereby emerging from
latency. Thus, in the absence of effective functional immune responses, as occurs in
immunocompromised or immunoimmature individuals, both HCMV primary infections
and reactivations from latency can cause significant morbidity and mortality. However,
even in immunocompetent hosts, HCMV represents a relevant risk factor for the
development of several chronic inflammatory diseases and certain forms of neoplasia.
HCMV infection may shift between the lytic and latent state, regulated by a delicate
and intricate balance between virus-mediated immunomodulation and host immune
defenses. Indeed, HCMV is a master in manipulating innate and adaptive host defense
pathways, and a large portion of its genome is devoted to encoding immunomodulatory
proteins; such proteins may thus represent important virulence determinants. However,
the pathogenesis of HCMV-related diseases is strengthened by the activities of bioactive
molecules, of both viral and cellular origin, that are secreted from infected cells and
collectively named as the secretome. Here, we review the state of knowledge on the
composition and functions of HCMV-derived secretomes. In lytic infections of fibroblasts
and different types of endothelial cells, the majority of HCMV-induced secreted
proteins act in a paracrine fashion to stimulate the generation of an inflammatory
microenvironment around infected cells; this may lead to vascular inflammation and
angiogenesis that, in turn, foster HCMV replication and its dissemination through host
tissues. Conversely, the HCMV secretome derived from latently infected hematopoietic
progenitor cells induces an immunosuppressive extracellular environment that interferes
with immune recognition and elimination of latently infected cells, thereby promoting
viral persistence. Characterization of the composition and biological activities of HCMV
secretomes from different types of infected cells will lay the foundation for future
advances in our knowledge about the pathogenesis HCMV diseases and may provide
targets for the development of novel antiviral intervention strategies.
Keywords: human cytomegalovirus, lytic infection, latency, bioactive molecules, secretome, chronic disease,
angiogenesis, immunoevasion
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THE HUMAN CYTOMEGALOVIRUS
Human cytomegalovirus (HCMV) is an opportunistic beta-
Herpesvirus that infects more than 90% of people worldwide
with an infection rate that increases with age (Landolfo et al.,
2003; Britt, 2008; Mocarski et al., 2014). HCMV infection, as
for the other human Herpesviruses, is characterized by two
phases: lytic and latent. Following primary infection, in which
the virus productively replicates in a broad range of different
cell types (Sinzger et al., 2008), HCMV establishes latency
in cells of myeloid lineage through a still poorly understood
mechanism (Britt, 2008; Crough and Khanna, 2009; Mocarski
et al., 2014). In the normal immunocompentent host, primary
infection is usually asymptomatic or mildly symptomatic and
persistent (Britt, 2008; Mocarski et al., 2014). Nevertheless,
HCMV infection is considered, even in immunocompetent
hosts, a risk factor for the development of various vascular
diseases, immunosenescence, and tumor development (Britt,
2008; Mocarski et al., 2014; Nogalski et al., 2014). In contrast, in
individuals in which the ability to develop an appropriate cellular
immune response is compromised, such as immunosuppressed
patients and the immunoimmature fetus during pregnancy,
HCMV infection is one of the major causes of morbidity
and mortality. Indeed, primary infection or reactivation from
latency causes overt diseases in immunosuppressed hosts, such
as transplant recipients taking immunosuppressive drugs and
AIDS patients. In these settings, HCMV can be responsible
for a wide range of clinical conditions, for example retinitis,
pneumonia, colitis, hepatitis, and several chronic inflammatory
diseases, such as atherosclerosis, transplant vascular sclerosis
(TSV), and chronic allograft rejection (CR; Britt, 2008; Crough
and Khanna, 2009; Mocarski et al., 2014). Congenital HCMV
infections, on the other hand, represent the most prominent viral
cause of birth defects such as malformations, hearing loss and
learning disabilities (Kenneson and Cannon, 2007; Britt, 2008;
Mocarski et al., 2014), and the incidence of HCMV transmission
to the fetus is strictly related to maternal seroprevalence. Primary
maternal infection carries a risk of transmission between 14.2
and 52.4% (Kenneson and Cannon, 2007), while a transmission
rate of 1.4% has been reported in relation to maternal reactivated
infections. However, the severity of congenital HCMV disease is
similar for both primary and non-primary infections (Ahlfors
et al., 2001; Rahav et al., 2007). Globally, the incidence of
HCMV congenital infection is between 0.3 and 2.3% of all live
births in developing countries. In congenitally infected fetuses,
about 10–15% develops evident symptoms after birth, with an
incidence of perinatal mortality of about 3–20 newborns per
100,000 live births, and of 24–160 cases of neurologic diseases
(hearing loss and mental retardation) per 100,000 neonates.
In the remaining 85–90% of HCMV-infected newborns, no
symptoms are displayed at birth, but late signs of infection,
such as hearing defects, are evident in 30–200 newborns per
100,000 live births. The impact of congenital HCMV infection
on public health is thus significant, given that hearing loss, the
most common long-term sequelae of infants with congenital
HCMV, it is the leading cause of non-genetic deafness in
children.
The broad range of clinical manifestations of HCMV diseases
reflects the capacity of the virus to productively infect an
extremely wide range of cell types in the host, such as skin
and lung fibroblasts, epithelial and endothelial cells (ECs),
vascular smooth muscle cells, hepatocytes, monocyte-derived
macrophages, neuronal, and glial cells, thus determining its
potential to spread to all areas of the body (Sinzger, 2008; Sinzger
et al., 2008).
The HCMV genome is the largest among the Herpesviruses;
its 235 kb double-stranded DNA is structured into a unique long
(UL) and a unique short (US) region, both of which are flanked
by terminal and internal inverted repeats (TRL/S and IRL/S,
respectively; Landolfo et al., 2003; Mocarski et al., 2014). Even
though its annotation remains provisional and its coding capacity
has recently been proposed to be much greater than originally
thought (Stern-Ginossar et al., 2012), it is generally accepted
that the HCMV genome encodes at least 170 canonical proteins
(Mocarski et al., 2014). Whole-genome functional profiling of
two HCMV laboratory strains revealed that a set of just 50
herpesvirus-common proteins, encoded by genes mainly located
in the central region of the UL domain, is required for productive
viral replication in primary fibroblasts (Murphy and Shenk, 2008;
Mocarski et al., 2014). The remaining two-thirds of canonical
HCMV protein-coding genes, mostly betaherpesvirus- or CMV-
specific, are confined within the terminal regions of the genome
and are not essential in cultured fibroblasts. Although, specific
functions have yet to be assigned to many of these non-essential
genes, they are mainly thought to be involved in regulating
virus cell tropism, dissemination, and viral persistence and
latency within the host, as well as the modulation of intrinsic,
innate, and acquired host immune responses, thus contributing
to viral pathogenesis in a variety of ways (Mocarski et al.,
2014).
During lytic infection, viral gene expression occurs in three
phases, named immediate early (IE or α), early (E or β), and
late (L or γ) in relation to their temporal kinetic profiles, and
leads to genome replication, assembly and release of mature
infectious viral particles. In brief, HCMV gene expression begins
with de novo expression of IE genes, predominantly IE1-72 and
IE2-86, that activate the expression of E genes, required for
replication of the viral genome and the subsequent transcription
of L (primarily structural) genes. IE2-86 protein autoregulates its
own expression by negatively acting on the Major IE Promoter
(MIEP) of HCMV (Figure 1; Stinski and Petrik, 2008); it binds to
the cis-repressive sequence (CRS) of MIEP, resulting in a decrease
in MIEP transcription (Stinski and Petrik, 2008). The activities of
IE proteins, in turn, determine the expression of E genes, which
are divided in two subgroups, β1 (E) and β2 (E-L), according
to their time of expression; their functions are mainly related
to HCMV replication machinery, viral DNA replication factors,
repair enzymes, and immune evasion (Landolfo et al., 2003;
Mocarski et al., 2014). L proteins are then expressed according
to two different kinetics profiles (γ1 and γ2), shaped by distinct
times of expression and their sensitivity to inhibitors of viral DNA
replication. L proteins functions are associated to the assembly,
maturation and egress of newly formed viral particles from the
host cell.
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FIGURE 1 | Regulation of HCMV MIEP activity during lytic and latent infections. (A) In cells permissive to lytic infection, the MIEP is associated with
acetylated histones (Ac; H4 and H3) and many constitutive and inducible cellular transcription factors (NF-κB, CREB, AP1, SRF, and Elk-1) bind to cognate binding
sites to activate IE genes transcription. (B) In latently infected cells, cellular transcriptional repressors (YY1, ERF, and Gfi-1) bind and recruit histone deacetylases
(HDAC1) and methyltransferases (HMT) to the MIEP. The reduced content of acetylated H4 and the increase of dimethylated H3 histones (Me), promotes recruitment
of the silencing protein (heterochromatin protein 1 -HP1β-), thus determining repression of the MIEP transcriptional activity.
In contrast to lytic replication, only a small subset of
HCMV genes are expressed during latency (e.g., transcripts
for the latency-associated viral IL-10/UL111A, LUNA [Latency
Unique Natural Antigen], US28, UL138, and UL144) without
any detectable production of infectious virus (Avdic et al., 2011;
Reeves, 2011; Poole et al., 2014). HCMV latency is restricted to
primary myeloid progenitors, such as granulocyte macrophage
progenitors (GMPs), CD34+ hematopoietic progenitor cells, and
CD14+ monocytes (Hahn et al., 1998; Scrivano et al., 2011;
Rossetto et al., 2013). In these infected cell-types the carriage of
viral DNA occurs in the absence of the expression of lytic genes
(Mocarski et al., 2014). Only upon the terminal differentiation of
these cells into macrophages or dendritic cells (DCs), HCMV lytic
genes are expressed: IE gene products activate the expression of
other genes, leading to viral DNA replication and de novo virus
production (Taylor-Wiedeman et al., 1994; Hahn et al., 1998;
Soderberg-Nauclér et al., 2001; Reeves et al., 2005; Britt, 2008;
Huang et al., 2012; Mocarski et al., 2014). Since the number of
cells carrying the latent viral genome is extremely low in vivo
(about 0.001–0.01% of monocytes), it has been necessary to
develop complex experimental latency models in order to study
the related mechanisms. Thus, experimental HCMV latency and
reactivation analyses have been performed using in vitro models
that exploit primary myeloid progenitors cells: namely GMP
cells, CD34+ hematopoietic cells, and CD14+monocytes (Reeves
et al., 2005; Cheung et al., 2006; Reeves and Sinclair, 2010; Liu
et al., 2013). All of these studies have highlighted that a crucial
aspect of HCMV latency is the repression of MIEP following
its association with repressive chromatin markers (Bain et al.,
2003; Wright et al., 2005; Sinclair and Sissons, 2006), involving
the recruitment of histones and transcriptional silencing factors
to the MIEP (Reeves, 2011). In addition to several binding sites
for cellular transcription factors (e.g., NF-κB, CREB/ATF, AP1,
SRF, Elk-1) that stimulate its transcriptional activity (Figure 1;
Caposio et al., 2007a, 2010; Lashmit et al., 2009; Isern et al.,
2011; Mocarski et al., 2014), the MIEP contains a series of
multiple binding sites for transcription factors that may lead to
its repression (YY1, ERF and Gfi-1; Figure 1; Reeves, 2011). In
fact, during HCMV latency, YY1 and ERF bind to MIEP, and
recruit histone deacetylases and methyltransferases than then
target histones associated with MIEP (Wright et al., 2005). The
methylated histones then become targets for the recruitment
of heterochromatin protein 1 (HP-1), which augments MIEP
repression and contributes to the establishment of latency (Liu
et al., 2010). Therefore, permissive or latent infection may be
determined by the balance between activating and repressive
transcription factors that control MIEP activity (Figure 1; Reeves
and Sinclair, 2013). However, this balance is thought to be
mainly under the control of host inflammatory responses, either
in immunocompetent or immunosuppressed individuals (Liu
et al., 2013). Various studies have indeed shown that HCMV
reactivation, during the allogeneic response to a transplanted
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organ, is mediated by the expression of inflammatory cytokines
(i.e., TNF, LPS, and IL-6) that may, in turn, activate MIEP-
interacting cellular transcription factors (e.g., NF-κB and AP-
1), thus promoting MIEP activation and lytic HCMV gene
expression (Hummel and Abecassis, 2002). However, in other
experimental systems, the induction of IE gene expression has
been associated with the state of cellular differentiation, as
observed in non-permissive monocytes upon their differentiation
into permissive macrophages in response to tumor necrosis factor
(TNF) and IFN-γ (Soderberg-Nauclér et al., 1997).
MODULATION OF HOST IMMUNE
RESPONSES BY HCMV
Among the HCMV genes not essential for growth in cultured
fibroblasts, about 40 have been shown to be involved in the
modulation of host immune responses to viral infection by
interfering with innate immune mechanisms and counteracting
adaptive antibody and T-cell mediated immunity (Mocarski et al.,
2014). The ability of HCMV to establish persistent infection,
in spite of a robust T-cell and neutralizing antiviral antibody
response, is mainly ensured by the activity of many virus-encoded
immunomodulatory proteins. HCMV immunomodulation is
therefore of pathogenetic importance in the establishment of
virus persistence in the host. In this regard, HCMV is considered
a master of immune evasion strategies, as highlighted by
the results of several functional genomic, transcriptomic, and
proteomic analyses that have defined many immunomodulatory
functions of several HCMV proteins. In particular, these viral
proteins have been observed to: (1) interfere with antigen
presentation by major histocompatibility complex-I (MHC-
I) molecules (e.g., the viral gene products US2, US3, US6,
US10, US11, and UL82); (2) permit immune evasion through
interference with and T and NK cells functions (e.g., the proteins
encoded by genes UL16, UL18, UL40, UL83, UL141, UL142,
US18, and US20); and (3) mimic the activities of cellular
cytokines/chemokines (e.g., proteins UL111A, UL128, UL146,
and UL147) or act as fake host cytokine/chemokine receptors
(as observed for proteins UL144, UL21.5, US27, US28, UL33,
and UL78; McSharry et al., 2012; Van Damme and Van Loock,
2014).
The best-characterized mechanisms of HCMV
immunoevasion can be summarized as follows:
(1) Interference with antigen presentation by MHC-I molecules.
A remarkable example is provided by glycoproteins
US2, US3, US6, and US11, characterized by a single
transmembrane (TM)-spanning and an immunoglobulin
(Ig) domain, which most likely arose by duplication of
a single viral ancestor gene (Gewurz et al., 2001). These
HCMV glycoproteins, when expressed in fibroblasts,
endothelial/epithelial cells, or DCs, induce, through
different mechanisms, a decrease in the cell-surface
expression of MHC-proteins required for the activation
of CD8+ T lymphocytes (Mocarski, 2002). In particular,
both US2 and US11 proteins are able to redirect nascent
MHC class I proteins from the ER into the cytosol until
ubiquitin-dependent proteasome-mediated degradation
occurs. The US2 glycoprotein has also been observed to
inhibit MHC class II protein translocation, thus inducing a
substantial block of CD4+ T cell expansion. On the other
hand, the US3 gene product prevents the egress of MHC
class I proteins from the endoplasmic reticulum (ER) to the
Golgi apparatus, whereas the US6 protein is able to bind
the transporter of antigen processing (TAP) in the lumen
of the ER, preventing ATP-dependent peptide loading on
the cell membrane (Mocarski, 2002). In conclusion, this
type of immunoevasion prevents the immune recognition of
HCMV-infected cells.
(2) Immune evasion through interference with T and NK
cells functions. Lytically HCMV-infected cells exhibit a
noteworthy resistance to NK cell-mediated cytolysis in vitro
(Wilkinson et al., 2008). HCMV is, in fact, able to alter and
modify NK cell activity through different ‘evasion’ strategies,
such as those exerted by: (i) UL16, a viral glycoprotein able
to directly bind and sequester in the ER MICB, ULBP1,
and ULBP2 -ligands for the activating NKG2D receptor
present on NK cells- thus preventing their expression on
the surface of HCMV-infected cells (Wilkinson et al., 2008);
(ii) UL18, a viral-MHC-I homolog, which was found to
bind the NK cell inhibitory receptor LIR1/ILT2 with a
1000-fold higher affinity than HLA-I molecules (Wilkinson
et al., 2008); (iii) UL40, a viral protein able to promote
the HLA-E upregulation on the surface of HCMV-infected
cells. Since HLA-E acts as a NK cell-mediated cytotoxicity
suppressor through the NK cell inhibitory receptor complex
CD94/NKG2A (Prod’homme et al., 2012), its upregulation
contributes to the NK cell immunoevasion of HCMV-
infected cells; (iv) UL83, that encodes for the major HCMV
tegument protein pp65 that suppresses the induction of
several interferons (IFNs) and proinflammatory chemokine
transcripts; pp65 may also directly bind to the activator
receptor NKp30, present on the surface of NK cells, thus
suppressing NK cell activation (Wilkinson et al., 2008);
(v) UL141, a viral glycoprotein able to sequester CD155
molecule in the ER. CD155 expression leads to NK cell
activation by binding to NK receptors CD226 and CD96
(Nemcˇovicˇová et al., 2013). Therefore, sequestration of
CD155 prevents NK cell activation and survival of infected
cells; (vi) US18 and US20 proteins recently observed to
promote lysosomal MICA degradation (Fielding et al., 2014).
MICA, the MHC class I polypeptide-related sequence A, is
a natural ligand of the NKG2D receptor. NKG2D-MICA
binding induces NK cell activation, leading to a cytolytic
response against HCMV-infected cells. Therefore, MICA
degradation reduces the capability of NK cells to recognize
infected cells (Fielding et al., 2014).
(3) Mimic physiological activities of cellular cytokines/
chemokines or host cytokine/chemokine receptors. HCMV
encodes several homologs of chemokine/cytokine and/or
their receptors that may interfere with the corresponding
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host counterparts. In this regard, an important example
of a HCMV-encoded chemokine receptor homolog is
represented by the multifunctional US28 protein. US28
is considered a putative immunoevasion molecule due to
its capability to bind and internalize a range of cellular
chemokines, including a broad spectrum of CC and CX3C
chemokines, thus limiting the ability of host chemotactic
molecules to elicit their effects in immune cells stimulation
(Mocarski et al., 2014). However, US28 makes use of
both the extracellular chemokine milieu and different
intracellular G-protein pathways to produce a wide variety
of pathophysiological cell responses (Beisser et al., 2008).
In fact, upon stimulation with some chemokines, US28
specifically promotes smooth muscle cells and macrophage
migration, thus contributing to both virus dissemination
and pathogenesis of HCMV-associated vascular diseases
(Vomaske et al., 2009). On the other hand, constitutive
expression of US28 induces, in a ligand-independent
manner, cyclooxygenase-2 (COX-2) expression via NF-κB
activation, leading to the production of VEGF, one of the
most abundant angiogenic factors (Maussang et al., 2009).
Moreover, the release of virus-encoded cytokines/chemokines
homologs (see HCMV-Induced Secreted Cellular Proteins)
permits the virus to modulate specific host immune defense
mechanisms in infected tissues, since these bioactive soluble
molecules act in a paracrine fashion.
BIOACTIVE MOLECULES RELEASED
FROM HCMV-INFECTED CELLS
The pathogenesis of acute HCMV diseases is related to end-
organ damage that results from both lytic virus replication and
host immune responses, whereas diseases associated to persistent
infections in both immunocompetent and immunocompromised
patients (transplant recipients and AIDS patients) are related
to chronic inflammation (Britt, 2008). However, besides the
direct cytopathic effect of virus replication on host tissues,
the pathogenesis of HCMV diseases may be influenced by the
activity of virus-induced molecules secreted from virus-infected
cells. These secreted factors, of both viral and cellular origin,
by acting in a paracrine fashion alter and modify the local
microenvironment, thus contributing to the development of
HCMV-related diseases (Streblow et al., 2008).
HCMV-Induced Secreted Cellular
Proteins
Early in vitro studies on the ability of HCMV to stimulate the
secretion of bioactive cellular factors identified several cytokines
and growth factors released from different types of infected
cells. First, Almeida et al. (1994) observed that HCMV infection
of HUVECs (Human Umbilical Vein Endothelial Cells) greatly
increased the expression of IL-6 mRNA and the secretion of this
cytokine into the supernatant of infected cells. Dengler et al.
(2000) went on to demonstrate the paracrine activity of IL-
1β released from HCMV-infected cells, which resulted in an
upregulation of pro-inflammatory adhesion molecules on non-
infected neighboring cells. In fact, by analyzing the expression
of plasma membrane proteins on the surface of both HCMV-
infected HUVECs and human vascular smooth muscle cells
(hvSMC), they observed a 200-fold overexpression of the Inter
Cellular Adhesion Molecule-1 (ICAM-1) and de novo induction
of both Vascular Cell Adhesion Molecule 1 (VCAM-1) and
E-selectin (Dengler et al., 2000). In regard to the EC model,
we observed an upregulation of ICAM-1, IL-8, CCL5/RANTES,
CXCL10/IP-10, CXCL11/I-TAC, and COX-2 gene expression in
HUVECs cells infected with a low-passage HCMV strain, thus
indicating a direct involvement of HCMV in the modification
of the extracellular vascular environment through the release of
inflammatory mediators (Caposio et al., 2007b).
Using astrocyte and microglia cell models, Maxim et al. (2001)
observed that HCMV stimulated the release of CCL2/MCP-1
and IL-8 in the supernatants of infected astrocytes, whereas
infection of microglia cells led to an increased secretion of TNF-
α, IL-6, CCL2/MCP-1, IL-8, CCL5/RANTES, and CCL3/MIP-1α.
These findings thus suggest the ability of infected astrocytes to
recruit microglia cells, through the release of the chemoattractant
CCL2/MCP-1 (Maxim et al., 2001).
However, a different picture emerged from the investigation of
the HCMV-mediated modulation of chemokine gene expression
in the context of HCMV retinitis – a virus-induced inflammation
of the retina characterized by vasculitis and retina degeneration
that leads to retinal detachment in immunocompromised hosts.
In the in vitro cell model provided by human retinal pigment
epithelial cells, Momma et al. (2003) observed, by means of
RT-PCR and ELISA assays, that HCMV infection caused an
upregulation of IL-8, whereas CCL2/MCP-1 and CCL7/MCP-
3 levels were downregulated. The authors thus suggested that
the altered secretion of IL-8, CCL2/MCP-1 and CCL7/MCP-3 by
retinal cells may be involved in the initiation and development
of the inflammatory process responsible for the pathogenesis of
HCMV retinitis. In this scenario, the increased secretion of IL-
8 may stimulate the recruitment and trafficking of leukocytes
to the site of infection within the retina; on the other hand,
the decrease in CCL2/MCP-1 and CCL7/MCP-3 levels in the
extracellular environment may limit the migration of leukocytes,
thus contributing to the virus escape of the host innate immune
response (Momma et al., 2003).
Together, these earlier studies demonstrated how HCMV is
able to alter in a cell-type specific manner the extracellular
microenvironment surrounding infected cells by stimulating the
secretion of cellular bioactive factors.
However, only after the introduction of high-throughput
large-scale proteomic approaches including antibody-based
arrays and liquid chromatography-mass spectrometry (MS/LC),
was it possible to drawn up an in-depth depiction of the
complexity of the bioactive molecules released upon HCMV
infection (Dumortier et al., 2008; Botto et al., 2011; Caposio
et al., 2011, 2013; Fiorentini et al., 2011; Mason et al., 2012;
MacManiman et al., 2014; Noriega et al., 2014; Gustafsson et al.,
2015). These global biochemical characterizations confirmed
the cell-type specific patterns of secreted cellular factors from
HCMV-infected cells and most of the alterations of types and
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quantities of bioactive molecules already observed in earlier
studies.
Thanks to proteomics studies, the entire array of bioactive
proteins of present in supernatants from different types of
HCMV-infected cells, has now been defined, qualitatively and
quantitatively, and designated the HCMV secretome (Streblow
et al., 2008).
In the first of these studies, Dumortier et al. (2008) analyzed
virus-free supernatants from lytically infected fibroblasts
(NHDF) to investigate the complexity and heterogeneity
of the HCMV-induced secretome. Using gel-free liquid
chromatography (LCQ)-MS-MS, they identified more than
1,200 proteins in the secretome of HCMV-infected cells.
Among them, several factors involved in angiogenesis (AG)
and wound healing (WH) were further confirmed using a
wide range human cytokine antibody array (RayBio G Series
2000 arrays). A conspicuous number of cytokines (IL-5, IL-6,
IL-1α, IL-1β, GM-CSF, osteoprotegerin, TNF-α, TNF-RI and
-RII), growth factors (angiopoietin, angiotensinogen, FGF,
GDNF, HGF, IGF-BP, osteopontin, PDGF, PIGF, SPARC, and
VEGF), extracellular matrix proteins, chemokines (IL-8/CXCL8
and CXCL1/GRO-α), enzymes, and adhesion molecules were
identified (Table 1). The biological effects of HCMV secretome-
derived proteins on AG and WH were then assessed using
a modified matrigel in vitro tubule formation assay and an
electric WH assay, respectively (Dumortier et al., 2008).
However, many of the identified factors in the NHDF-derived
secretome are also involved in the inflammatory response
and EC activation, thus leading to cell proliferation, adhesion,
and inflammatory response, all of which are indeed linked to
TVS pathogenesis (Figure 2; Dumortier et al., 2008; Streblow
et al., 2008). Thus, it was suggested that HCMV infection alters
the local microenvironment through the secretion of cellular
factors from infected cells that, in turn, by acting in a paracrine
fashion, may stimulate AG and WH, both associated to the
development of vascular diseases, such as TVS (Streblow et al.,
2008).
Subsequent work by Botto et al. (2011) analyzed the
secretome of infected HUVECs and identified by means of
a cytokine/growth factors antibody array, 29 soluble factors,
including IL-6, GM-CSF, and IL-8/CXCL8. A comparison of
the HCMV secretomes derived from NHDF and HUVEC,
highlighted that the presence in both secretomes of abundant
cytokines/chemokines involved in AG, such as IL-6, GM-CSF,
IL-8/CXCL8, CCL4/MIP-1β, CCL7/MCP-3, CCL20/MIP-3α, and
CXCL11/I-TAC (Dumortier et al., 2008; Botto et al., 2011;
Caposio et al., 2011, 2013). Among the EC-derived factors,
IL-6 was identified as the major bioactive molecule involved
in neovessel formation since its selective depletion severely
decreased tubule formation (Botto et al., 2011). IL-6 is an
inflammatory cytokine involved in different pathophysiological
contexts, such as inflammation, lymphocytes differentiation, cell
proliferation, and the inhibition of apoptotic signals (Scheller
et al., 2011). IL-6 binding to its receptor (gp130) activates three
different intracellular transduction pathways: (i) the JAK/STAT
cascade, involved in growth regulation, survival, differentiation,
and long-term inflammation-promoting effects (Horvath, 2004);
(ii) the ERK1/2-MAPK pathway, and (iii) the phosphoinositol
3-kinase (PI3K)/Akt pathway, both of which are implicated in
the regulation of cell growth and differentiation (Wegiel et al.,
2008; Rose-John, 2012). In particular, IL-6 binding to its receptor
leads to the phosphorylation of STAT3, which subsequently
prevents apoptosis by blocking the activation of caspase 3
and 7, and most importantly, by increasing the expression of
an apoptosis inhibitor, such as survivin (Hodge et al., 2005).
Addition of the secretome derived from HCMV-infected ECs to
uninfected ECs was found to stimulate expression of survivin,
while antibody neutralization of IL-6 in the same secretome,
abolished its capability to induce survivin or activate caspase 3
or 7 (Botto et al., 2011). Therefore, it was concluded that EC-
derived HCMV secretome promotes EC survival through the
expression of survivin via activation of the IL-6 pathway (Botto
et al., 2011).
At the same time, in a study aimed at investigating the
susceptibility of lymphatic endothelial cells (LECs) to HCMV
infection, we characterized in detail the secretome of this
particular type of EC (Fiorentini et al., 2011). Although, early
reports have shown the presence of HCMV antigens and
DNA in lymphoid tissues, the ability of HCMV to infect
LECs remained unaddressed due to the lack of a suitable
in vitro system. In this study, we observed that a clinical
isolate of HCMV productively infected purified lymph node-
derived LECs and dysregulated the expression of several LEC
genes involved in the inflammatory response to viral infection
(Fiorentini et al., 2011). Qualitative and quantitative cytokine
antibody array analysis of virus-free supernatants from HCMV-
infected LECs revealed the virus-induced secretion of several
cytokines, chemokines, and growth factors that may be involved
in the regulation of EC physiological properties. Among the
released bioactive cellular proteins, the 20 most abundant
included several cytokines (IL-1α, IL-3, IL-5, IL-6, IL-13, IL-
15, GM-CSF, and TNF-β), several chemokines (CCL1/I-309,
CCL7/MCP-3, CCL20/MIP-3α, CXCL1/GROα, CXCL5/ENA-78,
CXCL9/MIG, and CXCL11/I-TAC), receptors (ICAM-1 and
TNF-R1), and growth factors (TGF-β1 and bFGF). Functional
assays then allowed us to establish that the secretome produced
by HCMV-infected LECs indeed stimulated AG in both LECs
and blood vessel ECs. Furthermore, neutralization of either
IL-6 or GM-CSF in the secretome brought about the loss
of its angiogenic properties. Involvement of IL-6 and GM-
CSF in the HCMV-mediated lymphoangiogenesis was further
supported by the finding that recombinant IL-6 and GM-CSF
reproduce the same angiogenic effects as seen for the whole LEC-
derived secretome. Thus, these results suggest that HCMV can
stimulate both hemangiogenesis and lymphangiogenesis through
an indirect mechanism that relies on the stimulation of IL-6 and
GM-CSF secretion from virus-infected cells (Fiorentini et al.,
2011).
A comparison of the HCMV-secretomes from different types
of ECs (LECs and HUVEC) and fibroblasts (NHDF) highlights
the presence of several common factors involved in both
AG and WH processes, such as IL-6, GM-CSF, CCL7/MCP-3,
CCL20/MIP-3α, CCL4/MIP-1β, and CXCL11/I-TAC (Table 1;
Caposio et al., 2013).
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TABLE 1 | The most abundant bioactive factors determined by Ray Biotech protein assay analysis in the secretome of lytic HCMV-infected cells.
Cell types
Classification Symbol Gene annotation Biological function NHDF1 HUVEC2 LEC3
Cytochine/chemochine CXCL1; GROα Chemokine (C-X-C motif) ligand 1 Chemoattractant for neutrophils • • •
CXCL5; ENA-78 Chemokine (C-X-C motif) ligand 5 Recruitment and activation of leukocytes • •
CXCL6; GCP-2 Chemokine (C-X-C motif) ligand 6 Chemoattractant for neutrophilic granulocytes •
CXCL9; MIG Chemokine (C-X-C motif) ligand 9 Leukocyte trafficking •
CXCL10; IP-10 Chemokine (C-X-C motif) ligand 10 Stimulation of monocytes, natural killer, and
T-cell migration
• •
CXCL11; I-TAC Chemokine (C-X-C motif) ligand 11 Chemoattractant • • •
CXCL16 Chemokine (C-X-C motif) ligand 16 Recruitment of leukocytes • •
CCL1; I-309 Chemokine (C-C motif) ligand 1 Leukocyte trafficking •
CCL3; MlP-1α Chemokine (C-C motif) ligand 3 Inflammatory responses • •
CCL4; MlP-1β Chemokine (C-C motif) ligand 4 Chemokinetic and inflammatory functions • • •
CCL5; RANTES Chemokine (C-C motif) ligand 5 Chemoattractant for blood monocytes,
memory T helper cells and eosinophils
• •
CCL7; MCP-3 Chemokine (C-C motif) ligand 7 Chemoattractant for macrophages • • •
CCL8; MCP-2 Chemokine (C-C motif) ligand 8 Leukocyte trafficking • •
CCL15; MIP-1δ Chemokine (C-C motif) ligand 15 T-cells and monocyte chemoattractant •
CCL20; MIP-3α Chemokine (C-C motif) ligand 20 Leukocyte trafficking • • •
CCL23; MPIF-1 Chemokine (C-C motif) ligand 23 Chemotactic activity on resting T
lymphocytes and monocytes
•
IL-1α Interleukin-1α Role in immune responses and inflammatory
processes
•
IL-3 Interleukin-3 Role in cell growth, differentiation, and
apoptosis
•
IL-5 Interleukin-5 Growth and differentiation factor for B cells
and eosinophils
• •
IL-6 Interleukin-6 Anti-inflammatory cytokine • • •
IL-8 Interleukin-8 Leukocyte trafficking • •
IL-10 Interleukin-10 Anti-inflammatory cytokine •
IL-13 Interleukin-13 Anti-inflammatory cytokine •
IL-15 Interleukin-15 T and natural killer cells activation and
proliferation
•
LTA; TNF-β Lymphotoxin A Proinflammatory cytokine •
TNF-α Tumor necrosis factor alpha Proinflammatory cytokine • •
Osteoprotegerin PG/TNFRSF11B Lymph-node organogenesis and vascular
calcification
• •
Growth factor GM-CSF Granulocyte-Macrophage
Colony-Stimulating-Factor
Bone and cartilagine development • • •
bFGF Fibroblast Growth Factor 2 (basic) Mitogenic and angiogenic activities •
TGF-β1 Transforming growth factor beta 1 Cell growth, proliferation, differentiation,
adhesion, and migration
• •
HGF Hepatocyte growth factor Angiogenesis •
Receptor ICAM-1 Intercellular adhesion molecule 1 Cell adhesion for endothelial and immune
system cells
• • •
TNF-RI Tumor necrosis factor receptor 1 Regulator of inflammation • •
TNF-RII Tumor necrosis factor receptor 2 Regulator of inflammation •
ECM MMP-1 Matrix metallopeptidase 1 Disruption of extracellular matrix • •
TIMP-1 TIMP metallopeptidase inhibitor 1 Inhibitor of the matrix metalloproteinases •
TIMP-2 TIMP metallopeptidase inhibitor 2 Inhibitor of the matrix metalloproteinases •
TIMP-4 TIMP metallopeptidase inhibitor 4 Inhibitor of the matrix metalloproteinases •
Enzyme ANG Angiogenin, ribonuclease, RNase A
family, 5
Angiogenesis •
Frontiers in Microbiology | www.frontiersin.org 7 May 2016 | Volume 7 | Article 715
fmicb-07-00715 May 12, 2016 Time: 17:53 # 8
Luganini et al. HCMV Secretome Regulates Viral Infections
FIGURE 2 | The role of endothelial cell-derived HCMV secretome in accelerating vascular diseases. Productive HCMV infection of endothelial cells leads to
the release of many bioactive proteins that can modify the microenvironment around host cells. The ability of these secreted factors to promote neo-vessel formation,
wound healing, and the inflammatory response may help explain the role of HCMV infection in the development of HCMV-associated vascular diseases.
Taking into consideration the results of the aforementioned
studies, the overall effect of HCMV-derived secretomes on AG
and WH in ECs is very likely related to the combination
of experimental conditions and different bioactive factors,
which may cooperate in a synergetic manner. In this regard,
Gustafsson et al. (2015) recently observed the influence of
different experimental settings, such as the cell type from which
the HCMV-secretome is derived, the culture conditions, the
time points of supernatant collection, and the concentration
of relevant bioactive molecules, in promoting AG and WH in
cultured ECs.
Whilst a number of studies have provided evidence for
functional roles of HCMV-derived secretomes produced by
lytically infected fibroblasts and ECs (Dumortier et al., 2008;
Botto et al., 2011; Fiorentini et al., 2011; MacManiman et al.,
2014), little is known about the activities of secretomes released
from latently HCMV-infected cells. However, exploitation of
a new experimental in vitro model of HCMV latency allowed
Mason et al. (2012) to obtain some first insights into how
latent infection is able to stimulate the release of bioactive
molecules. This experimental model involves the infection
of CD34+ hematopoietic progenitor cells cultivated in the
absence of stimuli that may promote their differentiation
into mature DCs or macrophages, that are fully permissive to
lytic HCMV infection. These experimentally latently infected
CD34+ cells showed long-term carriage of viral genomes in
which the MIEP remained associated with transcriptionally
repressive chromatin, thus hampering further HCMV lytic gene
expression. These observations correlate with those made ex
vivo of natural HCMV latent infections (Reeves et al., 2005),
and provide evidence in support of the use of experimentally
latently infected CD34+ cells as an effective model for the
study of HCMV latent infection and reactivation (Reeves
et al., 2005; Reeves and Sinclair, 2010). Indeed, analysis of
supernatants from HCMV-infected CD34+ cells by large-scale
cytokine antibody array has revealed the presence of many
bioactive cellular proteins known to be involved in both
regulation of the immune response and chemoattraction of
T cells (Table 2). The most highly abundant cellular factors
identified in this latent HCMV-secretome included: several
cytokines/chemokines (XCL1/LYMPHOTACTIN, CXCL9/MIG,
CXCL12/SDF-1, CXCL13/BLC, CCL1/I-309, CCL2/MCP-1,
CCL8/MCP-2, CCL13/MCP-4, CCL15/MIP-1δ, CCL17/TARC,
CCL20/MIP-3α, CCL27/CTACK, IL-8, IL-10/CSIF, IL-13, IL-15,
LEPTIN, LTA/TNF-β, and TNF-α), growth factors (BMP-4,
BMP-6, CSF-1/M-CSF, IGF-1/MGF, IGFBP3/IBP3; NT-3/NTF3,
TGF-β1, and TGF-β3), a receptor (ICAM-1), and the angiogenic
RNase angiogenin. However, an increase in secreted CCL2
was also observed from latently infected GMPs, and related
to the stimulation of CD14+ monocytes migration toward the
site of latency (Stern and Slobedman, 2008); whereas secretion
of both CCL2 and CCL8 was measured during a short-term
experimental latent infection of CD14+ monocytes, and linked
to the recruitment of CD14+ monocytes and CD4+ Th1 cells to
latently infected cells (Noriega et al., 2014). Functional analysis
of the HCMV-secretome derived from latently infected CD34+
cells, however, highlighted that chemoattraction of CD4+ T cells
exclusively depended on the binding of CCL8 to CC chemokine
receptors CCR3 and CCR5 expressed on CD4+ T cells. In fact,
the depletion of CD4+ T cells bearing CCR3 or CCR5 receptors,
as well as treatment of the secretome with a neutralizing anti-
CCL8 antibody, resulted in a substantially blockade of CD4+
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TABLE 2 | Main bioactive proteins assessed in the HCMV secretome of latently infected CD34+ cells.
Classification Symbol Gene annotation Biological function
Cytochine/chemochine XCL1; LTN Chemokine (C motif) ligand 1 Leukocyte trafficking
CXCL9; MIG Chemokine (C-X-C motif) ligand 9 Leukocyte trafficking
CXCL12; SDF1 Chemokine (C-X-C motif) ligand 12 Leukocyte trafficking
CXCL13; BLC Chemokine (C-X-C motif) ligand 13 B lymphocyte chemoattractant
CCL1; I-309 Chemokine (C-C motif) ligand 1 Leukocyte trafficking
CCL2; MCP-1 Chemokine (C-C motif) ligand 2 Leukocyte trafficking
CCL8; MCP-2 Chemokine (C-C motif) ligand 8 Leukocyte trafficking
CCL13; MCP-4 Chemokine (C-C motif) ligand 13 Leukocyte trafficking
CCL15; MIP-1δ Chemokine (C-C motif) ligand 15 T-cells and monocyte chemoattractant
CCL17; TARC Chemokine (C-C motif) ligand 17 T cells chemotaxis and trafficking
CCL20; MIP-3α Chemokine (C-C motif) ligand 20 Leukocyte trafficking
CCL27; CTACK Chemokine (C-C motif) ligand 27 T-cell-mediated inflammation, T lymphocyte chemoattractant
IL-8 Interleukin-8 Leukocyte trafficking
IL-10; CSIF Interleukin-10 Anti-inflammatory cytokine
IL-13 Interleukin-13 Anty-inflammatory cytokine
IL-15 Interleukin-15 T and natural killer cells activation and proliferation
LEP Leptin Angiogenesis and wound healing
LTA; TNF-β Lymphotoxin A Proinflammatory cytokine
TNF-α Tumor necrosis factor alpha Proinflammatory cytokine
Growth factor BMP-4 Bone morphogenetic protein 4 Bone and cartilagine development
BMP-6 Bone morphogenetic protein 6 Bone and cartilagine growth
CSF-1; M-CSF Colony stimulating factor 1 Monocytes proliferation, differentiation, and survival
IGF-1; MGF Insulin-like growth factor 1 Cell growth and development
IGFBP3; IBP3 Insulin-like growth factor binding protein 3 Cell growth and development
NT-3; NTF3 Neurotrophin-3 Neurogenesis
TGF-β1 Transforming growth factor beta 1 Cell growth, proliferation, differentiation, adhesion and migration
TGF-β3 Transforming growth factor beta 3 Cell adhesion, proliferation, differentiation
Receptor ICAM-1 Intercellular adhesion molecule 1 Cell adhesion for endothelial and immune system cells
Enzyme ANG Angiogenin, ribonuclease, RNase A family Angiogenesis
T-cell migration toward latently infected cells (Mason et al.,
2012). Moreover, in the same HCMV-secretome, high levels of
TGF-β and cIL-10, both involved in the induction of immune
tolerance by suppressing proliferation and T-cells functions were
detected (Bettini and Vignali, 2009). This observation, led to
the hypothesis that the secretome of latently infected CD34+
cells may create an immunosuppressive microenvironment, thus
interfering with the immune recognition of latently infected
CD34+ and promoting viral persistence. This hypothesis was
indeed supported by the finding that TGF-β and cIL-10 in
the latent secretome inhibited both the CD4+ Th1-mediated
cytotoxicity and the production of antiviral Th1-type cytokines,
such as IFN-γ, TNF-α, and TNF-β. Furthermore, treatment
of latent secretome with neutralizing antibodies specific for
cIL-10 and TGF-β significantly restored IFN-γ production and
the cytotoxic functions of CD4+ cells, thus confirming that the
observed inhibition of CD4+ T cells functions strictly depended
on the secretion of TGF-β and cIL-10 by latently infected CD34+
cells (Mason et al., 2012). In addition, cIL-10 may prevent cell
death and promote survival of latently infected cells (Weber-
Nordt et al., 1996; Poole et al., 2011), since it was observed
that cIL-10 is required for upregulation of the anti-apoptotic
protein PEA-15 – which abolishes FAS-induced apoptosis
(Poole et al., 2015). As described in Section “HCMV-Induced
Secreted Cellular Proteins” above, the viral homolog LAvIL10
also stimulates the release of cIL-10 in latently infected CD34+
cells. Subsequently, cIL-10 may downregulate the expression of
cellular microRNA hsa-miR-92a, thus inducing the secretion of
the cellular CCL8 (Poole et al., 2014). Together these findings
suggest that TGF-β and cIL-10 in the latent HCMV secretome by
acting in a paracrine manner on uninfected bystander CD34+
cells, create and further expand a microenvironment conducive
to the latent carriage of HCMV genomes. In fact, it was observed
that uninfected CD34+ cells synthetized TGF-β and cIL-10,
when cultured in the presence of the latent secretome (Mason
et al., 2012). Overall, these findings support the existence of a
complex virus strategy during latency aimed at the generation
of a heavily immunosuppressive microenvironment around
latently infected CD34+ that allows them to evade host immune
recognition (Figure 3). In fact, even if HCMV infections leads
to the recruitment of CD4+ T cells to site of latency through
the release of CCL8, it then inhibits their antiviral functions by
generating the strong immunosuppressive microenvironment,
thereby avoiding the elimination of latently infected cells
(Sinclair and Reeves, 2013). Furthermore, the upregulation of
cIL-10 protects latently infected CD34+ from apoptosis, thus
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FIGURE 3 | Human cytomegalovirus (HCMV)-derived secretome and virus latency. HCMV latency is established in bone marrow cells and is carried out in
CD34+ hematopoietic progenitor cells and in CD14+ monocytes. (A) Latently infected CD34+ cells secrete CCL2/MCP-1 and CCL8/MCP-2 cytokines that recruit
CD14+ monocytes and CD4+ Th1 cells to latently infected cells. However, the secretion of highly immunosuppressive cellular IL-10 and TGF-β inhibit proliferation
and the antiviral functions of CD4+ Th1 cells. (B) Upon differentiation of CD14+ monocytes into mature macrophages or dendritic cells, reactivation of HCMV IE
gene expression is promoted and the viral lytic gene program is initiated.
promoting their survival in order to maintain latent viral genome
carriage (Poole et al., 2015).
Although, HCMV lytic and latent host-cell interactions
involve different target cell types and viral genetic programs,
and lead to different outcomes, many bioactive factors are
common between the HCMV-induced secretome derived
from lytically and latently infected cells. In particular, various
cytokines/chemokines, such as CXCL9/MIG, CCL1/I-309,
CCL8/MCP-2, CCL15/MIP-1δ, CCL20/MIP-3α, IL-8, IL-10,
IL-13, IL-15, LTA/TNF-β, and TNF-α, the growth factor TGF-β,
the receptor ICAM-1, and the enzyme ANG are present in both
lytically- and latently-infected cells secretomes. However, the
presence of a set of common bioactive factors between the two
functionally different secretomes is of great interest considering
the opposite outcomes of both forms of infections; indeed,
we might hypothesize that some of the pathophysiological
alterations of the microenvironment surrounding HCMV-
infected cells that are induced by the bioactive molecules that the
two secretomes have in common, may occur during both lytic
and latent infection.
Secreted HCMV Proteins
Many viral-encoded secreted bioactive proteins have been
identified in the supernatants of herpesvirus-infected cells.
Among them, cytokine-like proteins, such as the viral
counterparts of cellular IL-10, IL-17, and IL-6 were found
in the supernatants from cells infected with Epstein–Barr virus
(EBV; Ryon et al., 1993; Swaminathan et al., 1993), herpesvirus
saimiri (Yao et al., 1995), or human herpesvirus-8 (HHV-8;
Neipel et al., 1997), respectively. In this section, we review the
main biochemical and functional features of the HCMV-encoded
proteins that have identified to date within the secretome of
infected cells.
UL21.5
This was the first protein of viral origin identified as a secreted
product in the supernatant of HCMV-infected cells (Müllberg
et al., 1999). UL21.5 mRNA is abundantly expressed at the
late stage of HCMV infection (Rawlinson and Barrell, 1993)
and is transcribed by two exons; the first encodes a signal
peptide of 20 amino acids followed by an additional sequence of
eight amino acids, while the second exon codes the remaining
75 residues. Intriguingly, UL21.5 mRNA is also packaged
into virions, thus suggesting a role of the encoded protein
even before the infecting viral genome reaches the nucleus
and becomes transcriptionally active (Bresnahan and Shenk,
2000).
Later, it was demonstrated that pUL21.5 is a soluble CC
chemokine receptor able to selectively bind CCL5/RANTES with
high affinity and thus preventing its interaction with cellular
receptors (Wang et al., 2004). pUL21.5 by acting as a secreted
receptor decoy even at a distance from infected cells, may
therefore counteract chemokine-mediated host antiviral response
(Wang et al., 2004).
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UL146 and UL147
UL146 and UL147 proteins are considered as potential viral
encoded CXC-chemokines due to the presence of putative signal
sequences, cysteine spacing, and (in pUL146 only) an ELR-CXC
sequence (glutamic acid -E-, leucine -L-, arginine -R-, nominated
the ELR sequence, upstream of the CXC motif). Such features
are common to cellular CXC cytokines, such as IL-8 and Gro-
α (Penfold et al., 1999; McSharry et al., 2012). Sequence analysis
of UL146 and UL147 proteins from the Toledo strain of HCMV
reveals 24 and 16% amino acid identity to IL-8 (McSharry et al.,
2012), respectively; accordingly, UL146 protein is also known as
vCXCL-1, and UL147 protein as vCXCL-2.
While the functions of UL147 have not yet been characterized,
light has been shed on those of UL146 (Miller-Kittrell et al.,
2007; Heo et al., 2015). vCXCL-1 (UL146) is a 117 amino
acids glycoprotein secreted into the culture medium with late
kinetics. The UL146 gene product is highly polymorphic among
low-passage strains (Heo et al., 2008) and absent in laboratory
strains of the virus, such as AD169 and Towne (Cha et al.,
1996). Recently, it was observed that vCXCL-1 is able to:
(i) induce calcium flux via CXCR2 (Heo et al., 2015); (ii)
selectively stimulate the expression of beta2 integrin (CD11b
and CD11c), responsible for the adherence of leukocytes to
the vascular endothelium through an interaction with ICAM-1
and for modulating the life span of neutrophils (Mayadas and
Cullere, 2005; Heo et al., 2015); (iii) induce the migration of
neutrophils in vitro (Heo et al., 2015); and (iv) upregulate CCL22,
a chemokine involved in chemotaxis in monocytes, dendritic and
NK cells, and chronically activated T lymphocytes (Heo et al.,
2015).
Together, the capability of vCXCL-1 to alter the trafficking of
HCMV-infected neutrophils, as potential HCMV carriers, may
facilitate viral dissemination and promote the spread of HCMV
through the host (McSharry et al., 2012).
UL128
The UL128 protein is part of the pentameric complex composed
of gH (pUL115), gL (pUL75), pUL130, and pUL131A that is
required for HCMV entry into epithelial, endothelial and DCs
(Revello and Gerna, 2010). However, pUL128 contains four
conserved cysteine amino acids at its N-terminus, similar to
those found in the CC-chemokines (Akter et al., 2003). To
this regard, it was observed that UL128 is able to induce the
migration of human PBMCs (peripheral blood mononuclear
cells) to levels comparable to those induced by the human
CCL3/MIP-1α chemokine (Zheng et al., 2012). In addition,
treatment with soluble pUL128 increases the expression of both
IL-6 and TNF-α in PBMCs, and stimulates PBMCs proliferation
through activation of the MAPK pathway (Zheng et al.,
2012). Alteration in PBMCs trafficking and cytokines secretion
by soluble pUL128 may thus facilitate HCMV dissemination
through the recruitment of infected carrier cells.
IL-10
Among the HCMV-encoded cytokine-like molecules, the
latency-associated viral cellular IL-10 homologu (LAcmvIL-10),
encoded by HCMV UL111A gene is worthy of note (Ouyang
et al., 2014). This HCMV gene encodes two IL-10 homologs
generated by alternative splicing (Kotenko et al., 2000; Jenkins
et al., 2004): cmvIL-10 of 175 amino acids, expressed during
productive infection with late kinetics (Spencer et al., 2002;
Chang et al., 2004), and LAcmvIL-10, of 139 amino acids, the
result of a C-terminal truncation, reported to be expressed
with early kinetics during both productive and latent infection
(Jenkins et al., 2004).
As the cellular IL-10 (cIL10), cmvIL-10, and LAcmvIL-10
downregulate the expression of MHC-II molecules in latently
infected GMPs (Spencer et al., 2008). However, cmvIL-10 shares
more functions in common with cIL-10 than LAcmvIL-10
(Jenkins et al., 2008b). In fact, cmvIL-10, but not LAcmvIL-
10, increases the expression of the IgG (FCγ) receptors CD32
and CD64, and increases FCγ receptor-mediated phagocytosis
(Jaworowski et al., 2009). Similar to cIL-10, cmvIL-10 then
inhibits the expression of proinflammatory cytokines in LPS-
stimulated MDDCs (Monocyte-Derived Dendritic Cells; Jenkins
et al., 2008a,b). Concerning the role of LAcmvIL-10, it was
recently observed that its expression in latently infected CD34+
cells resulted in the downregulation of cellular microRNA hsa-
miR-92a, which upregulates the myeloid transcription factor
GATA2 (Poole et al., 2013, 2014). GATA2, in turn, increases
the transcription of the latency-associated HCMV genes LUNA
and UL144 (Reeves, 2011; Poole et al., 2013), as well as the
transcription of the cellular IL-10 (Poole et al., 2011). Since cIL-10
is one of the most abundant cytokines in the secretome produced
by cells latently infected with HCMV, and believed to create
an immune suppressive environment and to suppress apoptosis
(Mason et al., 2012; Poole and Sinclair, 2015), LAcmvIL-10 is
thought to reduce the ability of CD4+ cells to recognize HCMV-
infected cells during latent infection (Mason et al., 2012; Poole
and Sinclair, 2015).
UL7
More recently, a novel HCMV-encoded secreted molecule,
the protein encoded by UL7 gene, has been identified as
a critical component of the HCMV-secretome responsible
for vascular dysregulation associated with persistent HCMV
infection (MacManiman et al., 2014). The UL7 gene belongs
to the RL11 family, located in the left end of the viral
genome, and characterized by early-late-phase kinetics during
lytic HCMV infection (Engel et al., 2011). Structure prediction
of UL7 protein identified a 222-amino-acid type I glycoprotein
characterized by a putative leader peptide (35 amino acids),
an extracellular immunoglobulin superfamily domain (Ig-like
domain; 102 amino acids), a mucine-like stalk region (55 amino
acids), a hydrophobic transmembrane sequence (22 amino acids)
and a short cytoplasmic tail (eight amino acids; Engel et al.,
2011). Engel et al. (2011) observed that the UL7 protein is
proteolytically cleaved in correspondence with the stalk region,
resulting in a heavily glycosylated ectodomain that is released
from infected cells. Interestingly, the UL7 Ig-like domain shares
significant amino acid identity with both CD229 (member of
SLAM family), which is involved in T-cell signaling (Engel et al.,
2011), and the carcinoembryonic antigen-related cell adhesion
molecule (CEACAM) protein, that is highly expressed during
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vasculogenesis (MacManiman et al., 2014). However, UL7 is
not able to bind directly CD229 or any other member of the
SLAM family, but it can contact a putative UL7 ligand on
the surface of monocyte-derived DCs, thus interfering with
pro-inflammatory responses (Engel et al., 2011). In particular,
UL7 has been observed to downregulate the production of
pro-inflammatory cytokines, such as TNF, IL-6, and IL-8 in
primary human monocyte-derived DCs and in the PMA-
induced myeloid cell lines, U937 and THP-1 (Engel et al.,
2011). These findings have thus suggested UL7 as a novel
HCMV-encoded product able to contribute to the inhibition
of the host antiviral defense in favor of the establishment of
persistent infection (Engel et al., 2011). Moreover, the activity
of CEACAM-1 in promoting vasculogenesis led MacManiman
et al. (2014) to hypothesize a potential role of UL7 in this
process. In support of this, using in vitro AG assays, they
found that the secretome generated by an UL7-deficient HCMV
produced a 50% reduction in tubulogenesis compared with that
for the secretome from wild-type virus. Furthermore, following
adenovirus-mediated transduction of human aortic endothelial
cells (HEACs) with either the full length UL7 or the UL7
ectodomain, they observed the appearance of a robust network
of interconnecting tubules, thus sustaining the involvement of
UL7, and in particular its ectodomain, in the promotion of
ECs differentiation (MacManiman et al., 2014). Moreover, the
observation of an increased secretion of IL-6 and the activation of
STATs and MAPK pathways in ECs overexpressing UL7 further
substantiates the role of UL7 in angiogenesis (MacManiman et al.,
2014). Taken together, these findings support a role of secreted
UL7 protein in regulating some physiological properties of ECs
and in the stimulation of angiogenesis.
The Importance of HCMV-Induced
Bioactive Molecules in Virus
Pathogenesis
Human cytomegalovirus infections are associated with the
acceleration of various long-term vascular diseases, especially
in immunocompromised hosts (Griffiths et al., 2015). In these
settings, HCMV has been correlated to the acceleration of a
number of vascular diseases, such as atherosclerosis, restenosis,
and TVS, which are all determinants of chronic rejection (CR),
one of the most important long-term conditions leading to graft
failure and re-transplantation (Grahame-Clarke, 2005; Streblow
et al., 2007). TVS is a complex phenomenon in which the
leading event is a diffuse and concentric intimal proliferation,
which, in turn, determines vessel occlusion due to perivascular
inflammation, ECs dysfunction, and hvSMC proliferation with
extracellular matrix deposition. In addition, the progression of
TVS is promoted by the same mechanisms that lead to AG
and WH (Streblow et al., 2007, 2008). In early TVS lesions,
macrophages, T cells, B cells, and NK cells are present, while
progression to late lesions is associated with a thinning intima
containing SMC and macrophages (Streblow et al., 2005). Strong
correlations between HCMV reactivation and the acceleration of
vascular diseases development have been made on the basis of: (i)
the high efficiency rate of infection for those cell types involved
in TVS, including EC, SMC, and monocyte-derived macrophages
(Lemström et al., 1993); (ii) the delay in the TSV progression and
a prolonged graft survival in transplant recipients after treatment
with ganciclovir, an approved anti-HCMV drug (Lemström et al.,
1997); and (iii) in vivo studies on CMV animal models (Lemström
et al., 1997; Streblow et al., 2003). In particular, in a rat model
of aortic allografts, it was observed that infection with rat
cytomegalovirus (RCMV) accelerates atherosclerosis, leading to
an overall rearrangement of both the structural and functional
architecture of vessel cells (Lemström et al., 1993; Streblow et al.,
2003), the reversal of these effects through the use of an anti-
CMV agent, such as ganciclovir, further support a role of the virus
in the pathogenesis of experimental atherosclerosis (Lemström
et al., 1994, 1997). RCMV infection has also been associated with
an altered profile of released cytokines, in which higher levels of
IL-2 and IL-4 were evident compared with controls (Zhou et al.,
1999).
Furthermore, the observation that the HCMV-secretomes
from both fibroblasts and ECs stimulate AG and WH in
in vitro models suggests that HCMV infection of the allograft in
transplant recipients and the subsequent release of a virus-altered
secretome may promote AG and WH in the host, thus resulting in
the acceleration of TVS (Streblow et al., 2008; Caposio et al., 2011,
2013). On the other hand, the stimulation of “de novo” lymphatic
and blood vessels sprouting may represent a strategy adopted by
the virus to enhance its replication and dissemination from the
initial infection site to other host tissues.
In contrast, the available data about the activities of the
HCMV-derived secretome from latently infected cells, indicate
that the generation of a secretome-induced immunosuppressive
microenvironment around latently infected cells may help
the virus escape recognition by the hosts’s immune system,
thus favoring cell survival, viral persistence and potential
reactivations.
Clearly, in both lytic and latent infections, the activities of
the wide range of bioactive molecules in HCMV-secretomes may
have severe pathogenetic consequences since they facilitate both
virus dissemination and persistence in the host in spite of a robust
antiviral response.
CONCLUSION
One of the main intriguing features of HCMV biology is the
exceptionally wide arsenal of virus-encoded proteins that have
been observed to be capable of counteracting host innate and
adaptive immune defenses. Persistence of the virus, even in
the immunocompetent host, and its ability to avoid immune
clearance may be due in part to the activities of the many
viral immunomodulatory proteins (Mocarski et al., 2014). In
this review, we have examined what is known about the
bioactive molecules, of both viral and cellular origin, secreted
from HCMV-infected cells. These proteins are able to modify
the extracellular environment of host infected tissues, thus
promoting both virus dissemination and persistence, as well as
some pathophysiological processes, such as AG and WH, that
may drive the development of associated vascular diseases.
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However, more work is needed to fully appreciate the importance
of HCMV-derived secretomes in the pathogenesis of HCMV
diseases.
To date, ECs, fibroblasts, and hematopoietic precursor cells
have been mainly used to investigate the composition and
functions of HCMV-derived secretomes; but, in the future, a
deeper understanding of the importance of the HCMV secretome
may come from the analysis of secretomes derived from other cell
types. For example, little is known about the impact of HCMV
infection on the secretion of bioactive molecules from epithelial
cells, which represent one of the main cell targets for productive
infection in the natural host. Does the HCMV-induced secretome
of epithelial cells able to alter the host’s immune recognition of
infected cells or to catalyze organ damage in relation to lytic
infection as occurs in the retina (Momma et al., 2003)?
The findings that we have reviewed here have led to a
better comprehension of both the viral and cellular bioactive
molecules involved in the host-HCMV relationship. Little is
known, however, about the molecular mechanisms underlying
the modulation and secretion of such cellular bioactive proteins.
For example, the HCMV mechanisms that interfere directly or
indirectly with the cellular secretion pathways remain to be
identified. Knowledge of these molecular dynamics would be
useful for the development of strategies aimed at attenuating or
blocking the ability of HCMV to interfere with the host immune
responses that contributes to the pathological outcome. Finally, it
will also be necessary to confirm the in vitro findings in in vivo
models, such as a humanized mouse model. The confirmation of
experimental data and hypotheses would support the rationale
to deepen our understanding of HCMV immunomodulation in
order to identify targets for novel therapeutic strategies to prevent
or control HCMV diseases.
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